{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:14:27Z","timestamp":1761513267074,"version":"3.38.0"},"reference-count":18,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2013,3,28]],"date-time":"2013-03-28T00:00:00Z","timestamp":1364428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Respir Dis"],"published-print":{"date-parts":[[2013,8]]},"abstract":"<jats:sec><jats:title>Background\/objective:<\/jats:title><jats:p> Recurrent hemoptysis is a debilitating complication of cystic fibrosis (CF) and likely results from mucosal erosions into abnormal bronchial blood vessels due to chronic respiratory infection. We hypothesize that the use of beta-blockade will decrease mean arterial pressure resulting in lower bronchial artery blood flow and, subsequently, decrease the frequency and severity of hemoptysis, rate of hospitalizations, and usage of intravenous antibiotics. <\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p> Retrospective chart review was performed on 12 CF patients with recurrent hemoptysis, aged 13\u201340 years old, along with a follow-up telephone survey to assess the effectiveness of beta-blockade for hemoptysis, tolerance of inhaled respiratory medications, activity tolerance, and potential adverse effects. A beta-blocker, specifically atenolol, was initiated in all subjects within 24 hours after experiencing recurrent hemoptysis episodes. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p> A majority of patients (72.7%) had complete cessation of hemoptysis. There were significant decreases in the frequency of hemoptysis ( p = 0.02) and the amount of hemoptysis ( p = 0.004). The rate of hospitalizations significantly decreased from 1.33 to 0.67 ( p = 0.05) after initiation of atenolol. There was a trend toward statistical significance in the reduction of intravenous antibiotics use ( p = 0.08). No statistical difference was found when comparing the pre- and post-treatment means of forced expiratory volume in 1-second ( p = 0.59). Very minimal adverse effects were observed with only one patient reporting intermittent facial flushing. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p> Beta-blockade, particularly with atenolol, appears to successfully treat, if not resolve, recurrent hemoptysis refractory to conservative therapy in CF. Beta-blocker therapy appears to maintain an effective safety profile in CF. <\/jats:p><\/jats:sec>","DOI":"10.1177\/1753465813482744","type":"journal-article","created":{"date-parts":[[2013,3,29]],"date-time":"2013-03-29T03:31:51Z","timestamp":1364527911000},"page":"217-223","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":11,"title":["Beta-blocker management of refractory hemoptysis in cystic fibrosis: a novel treatment approach"],"prefix":"10.1177","volume":"7","author":[{"given":"John","family":"Moua","sequence":"first","affiliation":[{"name":"Department of Pediatric Pulmonary, Miller Children\u2019s Hospital, Long Beach\/University of California, Irvine, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliezer","family":"Nussbaum","sequence":"additional","affiliation":[{"name":"Department of Pediatric Pulmonary, Miller Children\u2019s Hospital, Long Beach\/University of California, Irvine, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eileen","family":"Liao","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of California, Los Angeles, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inderpal S.","family":"Randhawa","sequence":"additional","affiliation":[{"name":"Miller Children\u2019s Hospital, Department of Pediatric Pulmonary\/Allergy and Immunology, 2801 Atlantic Avenue, Ground Floor, Long Beach, CA 90806, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2013,3,28]]},"reference":[{"key":"bibr1-1753465813482744","doi-asserted-by":"publisher","DOI":"10.1378\/chest.121.3.796"},{"key":"bibr2-1753465813482744","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2241010654"},{"key":"bibr3-1753465813482744","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1978.tb01647.x"},{"key":"bibr4-1753465813482744","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.97.10051173"},{"key":"bibr5-1753465813482744","first-page":"463","volume":"135","author":"Deffebach M.","year":"1987","journal-title":"Am J Respir Crit Care Med"},{"key":"bibr6-1753465813482744","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2007.11.007"},{"key":"bibr7-1753465813482744","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201002-0157OC"},{"key":"bibr8-1753465813482744","doi-asserted-by":"publisher","DOI":"10.1378\/chest.128.2.729"},{"key":"bibr9-1753465813482744","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2011-200067"},{"key":"bibr10-1753465813482744","doi-asserted-by":"publisher","DOI":"10.1097\/MOT.0b013e32833deca9"},{"key":"bibr11-1753465813482744","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003566.pub2"},{"key":"bibr12-1753465813482744","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/147.3.705"},{"key":"bibr13-1753465813482744","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d2549"},{"key":"bibr14-1753465813482744","doi-asserted-by":"publisher","DOI":"10.1055\/s-0028-1085931"},{"key":"bibr15-1753465813482744","first-page":"298","volume":"38","author":"Sommers Smith S.","year":"2002","journal-title":"Animal"},{"key":"bibr16-1753465813482744","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.09848.x"},{"key":"bibr17-1753465813482744","doi-asserted-by":"publisher","DOI":"10.1097\/01.RVI.0000222822.82659.50"},{"key":"bibr18-1753465813482744","doi-asserted-by":"publisher","DOI":"10.1148\/rg.226015180"}],"container-title":["Therapeutic Advances in Respiratory Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1753465813482744","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1753465813482744","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1753465813482744","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T09:45:56Z","timestamp":1740908756000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1753465813482744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,28]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["10.1177\/1753465813482744"],"URL":"https:\/\/doi.org\/10.1177\/1753465813482744","relation":{},"ISSN":["1753-4666","1753-4666"],"issn-type":[{"type":"print","value":"1753-4666"},{"type":"electronic","value":"1753-4666"}],"subject":[],"published":{"date-parts":[[2013,3,28]]}}}